Sitagliptin + Bevacizumab for Brain Cancer

This trial tests a new combination of drugs, sitagliptin (a diabetes medication) and bevacizumab (an anti-cancer drug), to determine their effectiveness in treating gliomas (a type of brain cancer) that have recurred or worsened after treatment. Researchers aim to identify the optimal dose of sitagliptin to use with bevacizumab. Individuals with a recurrent brain tumor, not currently on these drugs, and diagnosed with grade 4 glioma may be suitable candidates for this trial. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this novel combination therapy.

The trial information does not specify if you need to stop taking your current medications. However, it mentions that patients on full-dose anticoagulants can participate if they meet certain criteria, and those on investigational agents cannot participate. It's best to discuss your specific medications with the trial team.

Research has shown that bevacizumab, one of the drugs in this study, is usually well-tolerated by patients with recurring glioblastoma. Studies have found it can delay cancer progression and improve quality of life.

Unlike the standard of care for recurrent glioblastoma multiforme (GBM), which often includes treatments like temozolomide and bevacizumab alone, the combination of sitagliptin and bevacizumab introduces a unique approach. Sitagliptin, typically known for managing diabetes by inhibiting the enzyme DPP-4, may have a role in enhancing the effectiveness of bevacizumab by potentially impacting tumor growth pathways. Researchers are excited about this combination as it explores a novel mechanism of action that targets both blood vessel growth and metabolic pathways in cancer cells, which could lead to better outcomes for patients. This innovative approach has the potential to improve treatment efficacy and offer hope for a condition with limited options.

Research has shown that bevacizumab may help treat recurrent glioblastoma, a type of brain cancer, by extending the time patients live without the cancer worsening. Some studies found that this treatment improved the time patients lived without disease progression to between 42.6% and 50.3% at six months. Bevacizumab also reduces harmful immune cells, aiding the body's fight against tumors. In this trial, participants will receive a combination of bevacizumab and sitagliptin. Researchers are testing sitagliptin because it might enhance the immune response against these tumors. Although sitagliptin is still under investigation for this purpose, it targets specific pathways that could help fight gliomas when used with bevacizumab.³⁴⁵⁶⁷